Publications by authors named "Marta Alonso-Moreno"
Aim: Anemia, primarily due to iron deficiency, is a key risk factor in both elective and emergency surgeries. Immediate preoperative treatment with ferric carboxymaltose (FCM) in anemic patients can reduce the need for transfusions and the length of hospital stay, thereby optimizing surgical outcomes. The objective of this study was to assess the effectiveness and describe the use of administering intravenous FCM prior to elective scheduled surgery for patients diagnosed with anemia.
View Article and Find Full Text PDFUnlocking Hidden Awareness: Repurposing fMRI to Detect Levels of Consciousness.
J Undergrad Neurosci Educ
December 2023
Determining the state of consciousness in patients with disorders of consciousness is a challenging task because for someone to be deemed conscious, both wakefulness and awareness are required. Awareness has traditionally been assessed by examining physical responsiveness but in 2010, Monti et al. explored how using fMRI to measure brain activity in humans could help reclassify the state of consciousness in these patients.
View Article and Find Full Text PDFMigraine is considered one of the most disabling diseases. Currently, there are few studies on clinical migraine treatment based on sex-related differences, despite the important role of sex in migraine. Our aim was to evaluate gender bias in published clinical trials on monoclonal antibodies (erenumab, galcanezumab, fremanezumab and eptinezumab).
View Article and Find Full Text PDFArticle Synopsis
- Vancomycin PK/PD targets are currently unvalidated for neonates due to a lack of specific studies, prompting an analysis of its therapeutic regimen in this population.
- This observational study included 43 neonates treated with intravenous vancomycin for at least 72 hours, finding that 88.4% achieved clinical success, especially at certain AUC and trough concentration levels.
- Key findings suggest that a trough concentration of ≤6.8 μg/mL significantly correlates with poor clinical outcomes, while concentrations around 7 μg/mL and an AUC of ~240 mg·h/L are likely adequate for effective treatment in neonates.
Article Synopsis
- Crohn Disease (CD) is an inflammatory bowel condition linked to high levels of inflammatory cytokines, and treatments often include TNF-α inhibitors like adalimumab and certolizumab.
- This case report details a 65-year-old man with CD who developed erectile dysfunction (ED) correlated with two consecutive TNF-α treatments, which resolved upon switching to a different biologic drug, ustekinumab.
- The findings suggest that while similar biologics may have comparable effects, they can lead to different side effects, emphasizing the importance of medication choice in treating conditions like CD.
Vancomycin is used to treat a wide variety of infections within the pediatric population. In adults, continuous infusion of vancomycin (CIV) has been evaluated as an alternative to intermittent infusion of vancomycin (IIV) with potential advantages. In children, the use of CIV is increasing; however, data is currently limited.
View Article and Find Full Text PDFVancomycin is commonly used as a treatment for neonatal infections. However, there is a lack of consensus establishing the optimal vancomycin therapeutic regimen and defining the most appropriate PK/PD parameter correlated with the efficacy. A recent guideline recommends AUC-guided therapeutic dosing in treating serious infections in neonates.
View Article and Find Full Text PDFUnlabelled: Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is a rare hereditary systemic autoinflammatory disease (SAID). Treatment is based on corticosteroids, but often requires the addition of a biologic drug (anti-TNF agent, IL-1 receptor antagonist, etc) to achieve symptom control. The addition of the second drug is not clearly defined and must take into account the characteristics and preferences of the patient.
View Article and Find Full Text PDF